Potential first-in-class treatment is well-tolerated in patients with chronic hepatitis B

New data confirms that a novel first-in-class treatment for hepatitis B, called NVR 3-778, is well-tolerated and can reduce levels of the virus’ genetic material in the body when combined with pegylated interferon after four weeks of treatment.